Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BSF EnterpriseBSFAF EV-to-EBIT is -1.73 as of Aug. 08, 2026. The stock has 3 warning signs investors should review. Among 378 Biotechnology companies, BSF Enterprise ranks worse than 264550% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BSF Enterprise's Enterprise Value for the quarter that ended in Mar. 2026 was $3.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BSF Enterprise's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSF Enterprise EV-to-EBIT Related Terms
BSF Enterprise EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BSF Enterprise's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BSF Enterprise's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BSF Enterprise EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BSF Enterprise's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BSF Enterprise's EV-to-EBIT falls into.
BSF Enterprise's current Enterprise Value is $3.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BSF Enterprise's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSF Enterprise (BSFAF) has a EV-to-EBIT of -1.73 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BSF Enterprise and its competitors. According to the industry distribution chart, BSF Enterprise ranks #999999 out of 378 companies in the Biotechnology industry.
Is BSF Enterprise's EV-to-EBIT too high?
BSF Enterprise's current EV-to-EBIT is -1.73. Based on the distribution chart, BSF Enterprise ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does BSF Enterprise's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BSF Enterprise ranks #999999 out of 378 companies for EV-to-EBIT. This places BSF Enterprise in the lower half of its industry. The industry median EV-to-EBIT is 14.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.03, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BSF Enterprise and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BSF Enterprise's current EV-to-EBIT is -1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BSF Enterprise stock overvalued right now?
BSF Enterprise (BSFAF) has a current EV-to-EBIT of -1.73. The current EV-to-EBIT is -1.73. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BSF Enterprise (BSFAF), the current EV-to-EBIT is -1.73 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSFAF has been successfully added to your 
